🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,263 results for “Cancer” Clear

  1. Dinutuximab

    United Therapeutics Europe Ltd

    Small Cell Lung Cancer

    phase 3 mab completed

    1 trial

  2. Distress Thermometer and Problems List

    United Therapeutics Europe Ltd

    Cancer

    phase 3 other completed

    1 trial

  3. Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead Sciences International Limited

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  4. Drug: Ivonescimab Injection

    Summit Therapeutics

    Metastatic Colorectal Cancer (CRC)

    phase 3 small molecule active

    1 trial

  5. Durvalumab

    Arcus Biosciences

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  6. EIK1001

    Eikon Therapeutics

    Non Small Cell Lung Cancer (Squamous or Non Squamous)

    phase 3 small molecule active

    1 trial

  7. ELECTROLYTES , DURVALUMAB, VASOPRESSIN (ARGIPRESSIN) , PREDNISOLONE , INFLIXIMAB, MYCOPHENOLATE MOFETIL, PARACETAMOL , Tarlatamab, Tarlatamab, TOCILIZUMAB, ETOPOSIDE, DEXAMETHASONE, SILTUXIMAB, CARBOPLATIN, CISPLATIN

    Amgen Technology (Ireland) UC

    Extensive stage small cell lung cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  8. ELIGARD 45 mg, poudre et solvant pour solution injectable

    Cancer Prevention Pharma (Ireland) Limited

    Prostatic adenocarnicoma with high risk of recurrence

    phase 3 small molecule active

    1 trial

  9. ELOXATINE 5 mg/ml, solution à diluer pour perfusion, ELOXATINE 5 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    colon cancer and rectal with liver metastasis

    phase 3 small molecule active

    1 trial

  10. ERIBULIN MESYLATE, VINORELBINE, GEMCITABINE, CAPECITABINE, CAPECITABINE, Datopotamab deruxtecan

    AstraZeneca AB

    "Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy"

    phase 3 small molecule active

    1 trial

  11. ETOPOSIDE - Usual

    Lxo Ireland Designated Activity Company

    Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  12. ETOPOSIDE, ATEZOLIZUMAB, PF-08634404, CARBOPLATIN

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Extensive-Stage Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  13. ETOPOSIDE, Atigotatug + Nivolumab FDC, CARBOPLATIN, ATEZOLIZUMAB

    Bristol-Myers Squibb / Pfizer EEIG

    Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  14. ETOPOSIDE, PACLITAXEL, IFOSFAMIDE, CISPLATIN, CARBOPLATIN

    Cancer Prevention Pharma (Ireland) Limited

    Progressive or recurrent germ cell tumor (measurable or non-measurable)

    phase 3 small molecule active

    1 trial

  15. EVEROLIMUS, EVEROLIMUS, PF-07248144, FULVESTRANT, EVEROLIMUS, EXEMESTANE, FULVESTRANT, PF-07248144

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

    phase 3 small molecule active

    1 trial

  16. Eligard 22,5 mg poeder en oplosmiddel voor oplossing voor injectie

    Disc Medicine

    Patients with biochemical recurrence after primary treatment of prostate cancer presenting with =<4 metastases

    phase 3 small molecule active

    1 trial

  17. Enzalutamide

    China SXT Pharmaceuticals

    Metastatic Hormone Sensitive Prostate Cancer

    phase 3 small molecule active

    1 trial

  18. Erbitux 5 mg/mL solution for infusion, JNJ-61186372, Erbitux 5 mg/mL solution for infusion, VEGZELMA 25 mg/mL concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., BEVACIZUMAB

    Janssen-Cilag International N.V.

    KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  19. Erleada 240 mg film-coated tablets, Erleada 60 mg film-coated tablets, Docetaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Disc Medicine

    Metastatic hormone-sensitive prostate cancer

    phase 3 small molecule active

    1 trial

  20. EstroTep 500 MBq/mL, solution injectable

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Women with ER+ HER2- metastatic breast cancer who progressed on first line therapy with CDK4/6 inhibitor and aromatase inhibitor

    phase 3 small molecule active

    1 trial

  21. Everolimus

    China SXT Pharmaceuticals

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  22. Everolimus-ratiopharm® 2,5 mg Tabletten, GOSERELIN , ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets, LEUPRORELIN , DEXAMETHASONE , The investigational product is as follows: white tablets, elongated, flat, rounded edges, about 10 mm long and 4 mm wide, with the embossing "EV" on one side and "2.5" on the other side. The list of excipients of Placebo tablet is as follows: Lactose monohydrate, Polyplasdone, Cellulose microcrystalline, Magnesium stearate, Hypromellose., TRIPTORELIN

    Stemline Therapeutics B.V.

    patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors.

    phase 3 small molecule active

    1 trial

  23. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Gastric Cancer

    phase 3 small molecule active

    1 trial

  24. FILGRASTIM, CYCLOPHOSPHAMIDE, DOXORUBICIN, DEXRAZOXANE HYDROCHLORIDE

    Cancer Prevention Pharma (Ireland) Limited

    Advanced or metastatic soft tissue sarcoma (STS) in patients ≥65 years old

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources